Phoenix Biotech Acquisition Stock Total Asset
| PBAXUDelisted Stock | USD 10.87 0.00 0.00% |
Phoenix Biotech Acquisition fundamentals help investors to digest information that contributes to Phoenix Biotech's financial success or failures. It also enables traders to predict the movement of Phoenix Stock. The fundamental analysis module provides a way to measure Phoenix Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phoenix Biotech stock.
Phoenix |
Phoenix Biotech Acquisition Company Total Asset Analysis
Phoenix Biotech's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Phoenix Biotech Total Asset | 42.37 M |
Most of Phoenix Biotech's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phoenix Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Phoenix Biotech Acquisition has a Total Asset of 42.37 M. This is 99.98% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The total asset for all United States stocks is 99.86% higher than that of the company.
Phoenix Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phoenix Biotech's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phoenix Biotech could also be used in its relative valuation, which is a method of valuing Phoenix Biotech by comparing valuation metrics of similar companies.Phoenix Biotech is currently under evaluation in total asset category among its peers.
Phoenix Fundamentals
| Return On Asset | -0.0255 | |||
| Current Valuation | 66.05 M | |||
| Number Of Shares Shorted | 86 | |||
| Net Income | (2.52 M) | |||
| Cash And Equivalents | 553.77 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 650 K | |||
| Current Ratio | 13.88 X | |||
| Book Value Per Share | (2.20) X | |||
| Cash Flow From Operations | (1.71 M) | |||
| Short Ratio | 1.62 X | |||
| Beta | 0.044 | |||
| Total Asset | 42.37 M | |||
| Retained Earnings | (10.76 M) | |||
| Working Capital | 11.62 M | |||
| Z Score | -0.03 | |||
| Net Asset | 42.37 M |
About Phoenix Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phoenix Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phoenix Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phoenix Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |